Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study Group Clinical Trial
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Gianni Bisogno und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's and Children's Health, University of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Rhabdomyosarcoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, Fondazione Giovanni Celeghin Onlus, Padova, Italy, KickCancer Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Prognostic factors are crucial in tailoring treatments for patients with rhabdomyosarcoma (RMS). The European paediatric Soft tissue sarcoma Study Group (EpSSG) and the Children's Oncology Group (COG) employ similar prognostic factors, but utilize them differently resulting in diverse stratification systems. This diversity may result in dissimilar treatment approaches for comparable patients and hinder the comparison of clinical trial results. Procedure We reclassified 1993 patients enrolled in the EpSSG RMS 2005 and MTS 2008 studies based on the risk stratification used in current EpSSG and COG trials, and compared the type and cumulative doses of chemotherapy recommended to the different risk groups. Alkylating agents were compared using the cyclophosphamide equivalent dose formula. Metastatic RMS with high‐risk features were excluded because no standard recommended treatment exists.
Results
Patients were variably distributed across EpSSG and COG risk stratifications. Notably, 34.2% of EpSSG standard‐risk patients fell into three different COG risk groups (very low, low, and intermediate), and 66.8% of the total population, classified as standard, high, and very high risk by EpSSG, would all be considered intermediate risk by COG. Consequently, only 57.3% of the study population would receive comparable intensive chemotherapy under both EpSSG and COG protocols. Disparities emerged, with 16.5% undergoing more intensive and 17.2% receiving less intensive treatment in COG protocols compared to EpSSG studies.
Conclusions
Our study shows the complexities of the current RMS risk stratification systems, emphasizing the need for a global consensus. A unified approach would reduce the risk of disparate treatments for similar patients and facilitate more straightforward cross‐study comparisons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Women's and Children's Health, University of Padua, Padua, Italy.
- Pediatric Hematology Oncology Division, University Hospital of Padua, Padua, Italy.
- Department of Pediatric and Adolescent Oncology, Gustave-Roussy, Université Paris-Saclay, Villejuif, France.
- Division of Oncology, Hyundai Cancer Institute, Children's Hospital Orange County, Orange, California, USA.
- Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
- Children and Young People's Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, Surrey, UK.
ORCID-Profile: Gianni Bisogno, Veronique Minard-Colin, Josephine Haduong, Andrea Ferrari, Julia Chisholm
Förderung
- Intramural NIH HHS
- Fondazione Giovanni Celeghin Onlus, Padova, Italy
- KickCancer Foundation
- King Baudouin Foundation, Brussels, Belgium
Zitieren
APA
Bisogno, G., Minard-Colin, V., Haduong, J., Zanetti, I., Ferrari, A., Chisholm, J., Heske, C. M., Hladun, R., Jenney, M., Merks, J. H. M., & Venkatramani, R. (2025). Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study Group Clinical Trial. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31436
Vancouver
Bisogno G, Minard-Colin V, Haduong J, Zanetti I, Ferrari A, Chisholm J, et al. Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study Group Clinical Trial. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31436
BibTeX
@article{Bisogno2025,
author = {Bisogno, Gianni and Minard-Colin, Veronique and Haduong, Josephine and Zanetti, Ilaria and Ferrari, Andrea and Chisholm, Julia and Heske, Christine M and Hladun, Raquel and Jenney, Meriel and Merks, Johannes Hendrikus Maria and Venkatramani, Rajkumar},
title = {Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study Group Clinical Trial},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31436}
}
EUVIMED